Table 2.

General characteristic and results of the univariate analysis of risk factors associated with LC, PFS and OS

Parameters	No. of patients	LC		PFS		OS
		2-year rate (%)	p	2-year rate (%)	p	2-year rate (%)	p
Age (year)
<53	20	95.0	0.782	80.0	0.634	95.0	0.776
≥53	20	94.7		70.0		95.0
Gender
Male	29	100.0	0.016	72.4	0.868	96.6	0.644
Female	11	81.8		81.8		90.9
Histology
Squamous cell carcinoma	8	87.5	0.685	75.0	0.863	87.5	0.212
Non-keratinizing carcinoma	32	96.8		75.0		96.9
T stage
3	26	96.2	0.276	73.1	0.592	96.2	0.721
4	14	92.3		78.6		92.9
N stage
0-2	31	93.4	0.239	77.4	0.811	93.5	0.734
3	9	100.0		66.7		100.0
Treatment modality
Chemo + RT	21	95.0	0.086	76.2	0.594	95.2	0.968
Chemo + CCRT	19	94.7		73.7		94.7
HI-T
<2.9	23	100.0	0.028	100.0	<0.0001	100.0	0.022
≥2.9	17	87.8		41.2		88.2
SUVmax-T
<15.6	29	100.0	0.001	72.4	0.933	96.6	0.641
≥15.6	11	81.8		81.8		90.9
SUVmean-T
<4.7	23	100.0	0.006	69.6	0.929	95.7	0.942
≥4.7	17	88.2		82.4		94.1
MTV-T (ml)
<28.9	13	100.0	0.111	76.9	0.684	100.0	0.848
≥28.9	27	92.4		74.1		92.6
TLG-T (g)
<249.1	27	100.0	0.006	74.1	0.976	96.3	0.898
≥249.1	13	84.6		76.9		92.3
HI-N
<2.3	26	92.3	0.500	84.6	0.009	96.2	0.411
≥2.3	14	100.0		57.1		92.9
SUVmax-N
<7.6	20	95.0	0.692	75.0	0.672	95.0	0.891
≥7.6	20	94.7		75.0		95.0
SUVmean-N
<5.4	30	93.3	0.232	76.7	0.634	96.7	0.088
≥5.4	10	100.0		70.0		90.0
MTV-N (ml)
<11.1	28	92.9	0.125	78.6	0.907	96.4	0.270
≥11.1	12	100.0		66.7		91.7
TLG-N (g)
<80.4	32	93.6	0.235	75.0	0.429	93.8	0.770
≥80.4	8	100.0		75.0		100.0